ALS Phase II Study of NX210c

NCT06365216 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Amyotrophic Lateral Sclerosis

Interventions

DRUG: NX210c
DRUG: Placebo

Sponsor

Axoltis Pharma

Collaborators

[object Object]